Syros Pharmaceuticals (NASDAQ:SYRS) Stock Price Up 13.2%

Syros Pharmaceuticals Inc (NASDAQ:SYRS) rose 13.2% on Wednesday . The company traded as high as $9.99 and last traded at $9.93, approximately 222,770 shares were traded during mid-day trading. An increase of 25% from the average daily volume of 178,898 shares. The stock had previously closed at $8.77.

SYRS has been the subject of a number of research reports. Roth Capital initiated coverage on Syros Pharmaceuticals in a research note on Friday, July 12th. They issued a “buy” rating and a $17.00 price objective for the company. BidaskClub raised Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, July 12th. ValuEngine raised Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, June 26th. HC Wainwright reaffirmed a “neutral” rating on shares of Syros Pharmaceuticals in a research note on Thursday, May 2nd. Finally, Zacks Investment Research raised Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 9th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Syros Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $16.03.

The company has a market cap of $372.18 million, a PE ratio of -5.20 and a beta of 1.94. The stock’s fifty day simple moving average is $8.14. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.11 and a quick ratio of 8.11.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Thursday, August 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.06). The company had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.42 million. Syros Pharmaceuticals had a negative net margin of 3,137.55% and a negative return on equity of 79.79%. Equities analysts expect that Syros Pharmaceuticals Inc will post -1.94 earnings per share for the current fiscal year.

In related news, major shareholder Venture Fund Vii L.P. Arch sold 63,000 shares of Syros Pharmaceuticals stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $7.77, for a total value of $489,510.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 14.80% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in SYRS. BlackRock Inc. lifted its stake in shares of Syros Pharmaceuticals by 23.1% during the 4th quarter. BlackRock Inc. now owns 1,986,130 shares of the company’s stock worth $11,063,000 after purchasing an additional 372,462 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Syros Pharmaceuticals by 8.9% during the 4th quarter. Bank of New York Mellon Corp now owns 84,537 shares of the company’s stock worth $470,000 after purchasing an additional 6,883 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Syros Pharmaceuticals by 0.7% during the 4th quarter. Northern Trust Corp now owns 306,167 shares of the company’s stock worth $1,705,000 after purchasing an additional 2,179 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Syros Pharmaceuticals by 62.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 244,080 shares of the company’s stock worth $1,360,000 after purchasing an additional 93,728 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Syros Pharmaceuticals by 10.3% during the 4th quarter. Geode Capital Management LLC now owns 249,668 shares of the company’s stock worth $1,390,000 after purchasing an additional 23,234 shares during the last quarter. Hedge funds and other institutional investors own 65.27% of the company’s stock.

About Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

Featured Story: Why do company’s buyback their stock?

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit